Subscribe
istock-519319356_charlieaja
charlieAJA / iStockphoto.com
19 July 2017Big Pharma

Pharma organisations underline Brexit concerns in letter to negotiators

The Association of the British Pharmaceutical Industry (ABPI) and seven other UK and European life sciences bodies have jointly written to the UK and EU Brexit negotiators.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Brexit draft deal: a welcome step but more certainty needed, say lawyers
16 November 2018   While the pharmaceutical industry has welcomed the draft Withdrawal Agreement for the UK’s departure from the EU, more clarity is still needed, lawyers have told LSIPR.
Big Pharma
AstraZeneca seeks three-year Brexit transition period
5 October 2017   The chairman of pharmaceutical company AstraZeneca wants a transition period of three years following the UK’s exit from the EU.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Brexit draft deal: a welcome step but more certainty needed, say lawyers
16 November 2018   While the pharmaceutical industry has welcomed the draft Withdrawal Agreement for the UK’s departure from the EU, more clarity is still needed, lawyers have told LSIPR.
Big Pharma
AstraZeneca seeks three-year Brexit transition period
5 October 2017   The chairman of pharmaceutical company AstraZeneca wants a transition period of three years following the UK’s exit from the EU.

More on this story

Big Pharma
Brexit draft deal: a welcome step but more certainty needed, say lawyers
16 November 2018   While the pharmaceutical industry has welcomed the draft Withdrawal Agreement for the UK’s departure from the EU, more clarity is still needed, lawyers have told LSIPR.
Big Pharma
AstraZeneca seeks three-year Brexit transition period
5 October 2017   The chairman of pharmaceutical company AstraZeneca wants a transition period of three years following the UK’s exit from the EU.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB